non-steroidal mineralocorticoid receptor antagonist
Novo Nordisk acquires Corvidia Therapeutics for $1.3B to compete with Bayer’s Kerendia
Anika Sharma
Novo Nordisk, riding high on the success of its semaglutide sales, has taken a strategic leap by investing up to ...
